Pharmaceuticals
Youth at Risk of Being Left Behind in Asia Pacific Tuberculosis Response, Regional Forum Spotlights
Johnson & Johnson, together with the Global Fund and Asian Venture Philanthropy Network, convene 2nd annual Asia Pacific Tuberculosis Forum to advance progress toward ending tuberculosis in the region Youth are at risk of being missed from diagnosis if not engaged and empowered in fight against ...
2022-12-13 10:07
2459
CSL Announces Next CEO & Managing Director
Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from6 March 2023 MELBOURNE, Australia, Dec. 13, 2022 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed DrPaul McKenzie as Chief Executive Officer (CEO)...
2022-12-13 07:23
3192
Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19
--The exposure of active drug ASC10-A after twice daily dosing 800 mg double prodrug ASC10 in Chinese subjects was 94% of that after twice daily dosing 800 mg single prodrug molnupiravir in Japanese subjects --Based on Ascletis' Phase I results of ASC10 and molnupiravir's clinical efficacy data ...
2022-12-12 23:29
3640
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting
SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, presented the latest clinical data on Carteyva® (relmacabtagene autoleucel injection) in...
2022-12-12 18:00
4162
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer at SABCS 2022
* As of August 18, 2022，the confirmed ORR for 55 evaluable subjects was 76.4% and DoR was 24.0 months. The disease control rate was 100% in 55 evaluable subjects. * The median follow-up for PFS was 16.6 months. The median PFS was calculated as 25.4 months and yet to become mature. * The med...
2022-12-12 15:51
1679
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer at SABCS 2022
* As of Sep 10, 2022, 20 patients completed the surgery and pathological evaluation, tpCR rate were 50%, bpCR rate were 55.0%, and ORR were 100%. * In terms of safety, the incidence Grade ≥3 TEAE were 53.3% (16/30)。The incidence of SAE was 6.7% (2/30) with only one case related to KN026. SUZHO...
2022-12-12 15:00
1911
China further optimizes COVID-19 response with new measures
BEIJING, Dec. 12, 2022 /PRNewswire/ -- A report from People's Daily: Local authorities across China have soon made specific policies to implement the 10 new prevention and control measures recently rolled out by the country on further optimizing the COVID-19 response, so as to contain the epidemi...
2022-12-12 11:38
1941
Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022
* As of August 21, 2022, the ORR from 25 efficacy evaluable TNBC patients was 44.0%, the DCR was 96.0%, and the CBR was 52.0%. * The median follow-up time was 27.93 months. The median PFS was 7.33 months. Among the PD-L1 ≥1% pts, the median PFS was 8.61 months. * The median OS was not mature...
2022-12-12 10:33
2279
Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, Dec. 11, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2022-12-11 08:00
4566
Treadwell Therapeutics Announces A Presentation at the 2022 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor
NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced that data presented on the ongoing CFI-402257-CL-001 clinical study of the Company's CFI-402257 program in advanced solid...
2022-12-09 22:30
6388
Innovent Presents Phase Ib Clinical Data of IBI939 (Anti-TIGIT Monoclonal Antibody) in Previously Untreated PD-L1-selected NSCLC at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
ROCKVILLE, Md. and SUZHOU, China, Dec 9, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...
2022-12-09 08:00
2622
Innovent Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
ROCKVILLE, Md. and SUZHOU, China, Dec. 9, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2022-12-09 08:00
2659
Antengene Appoints Amily Zhang as its Chief Medical Officer
SHANGHAI and HONG KONG, Dec. 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
2022-12-08 08:30
2688
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA
--The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal Phase II/III in COVID-19 patients. Phase I clinical trial is expected to be completed within the first quarter of 2023 --Phase I clinical trial will also determine if ASC11 needs to be boosted by ...
2022-12-07 18:10
2708
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency The peer-reviewed publication heightens international understanding of APDS, a rare and recently characte...
2022-12-07 14:00
2728
Apollo Proton Cancer Centre successfully performs Asia's 1st Brain Bypass Surgery on twin children with Moya Moya Disease
CHENNAI, India, Dec. 7, 2022 /PRNewswire/ -- Apollo Proton Cancer Centre (APCC) recently performedAsia's first brain bypass surgery on twin 8-year-old children fromthe Netherlands. The integration of advanced technology and expertise at APCC helped the children to undergo surgery and recover quic...
2022-12-07 13:17
2736
Suvoda Launches eCOA-Specific Language and Design Toolkit as Solution Moves to Second Phase of Early Adopter Program
Practical, innovative functionality seeks to alleviate eCOA burdens, reduce time-to-launch, and improve site, clinician, and patient experience. PHILADELPHIA, Dec. 7, 2022 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic ar...
2022-12-07 08:00
1816
Parnell Pharmaceuticals Holdings Ltd Announces Commencement of Rights Offering
SYDNEY, Dec. 7, 2022 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") today commenced its previously announced backstopped rights offering to raise gross proceeds of approximatelyUS$4.0 million (the "Rights Offering"). Under the terms of the Rights O...
2022-12-07 07:00
2976
Turn Biotechnologies Changes Paradigm in Skin Rejuvenation
* Data unveiled at four industry conferences suggest a single ERA treatment may be more effective than combination therapies used today * Biomarker analysis demonstrates ERA's regenerative impact on fibroblast proliferation, collagen VII production * eTurna™ lipid-based delivery platform p...
2022-12-06 22:00
2554
CORVIA MEDICAL ANNOUNCES RANDOMIZATION OF FIRST PATIENT IN THE RESPONDER-HF CONFIRMATORY TRIAL
Corvia® Atrial Shunt has the potential to change the way heart failure is treated TEWKSBURY, Mass., Dec. 6, 2022 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the first patient has been randomized in RESPONDER-HF, a globa...
2022-12-06 20:04
1361
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
9065
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
7332
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
6976
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
6749
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
6707
